Form D · Biotechnology
Neurolens, Inc.
Coppell, TX · CIK 0001624178
Offering snapshot reported Sep 13, 2022 · SEC filing
- Reported sold
- $67.6M Offering amount: $67.6M
- Investors reported
- 31 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 1, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 13, 2022 | Initial | $67,642,795 | No comparison | 31 | SEC filing |
| Jun 27, 2022 | Amendment | $14,700,000 | $2,700,000vs Nov 17, 2021 | 27 | SEC filing |
| Nov 17, 2021 | Initial | $12,000,000 | No comparison | 9 | SEC filing |
| Mar 12, 2020 | Amendment | $23,819,972 | $824,993vs Dec 16, 2019 | 24 | SEC filing |
| Dec 16, 2019 | Amendment | $22,994,979 | $7,819,984vs Aug 7, 2019 | 20 | SEC filing |
| Aug 7, 2019 | Initial | $15,174,995 | No comparison | 7 | SEC filing |
| Dec 27, 2017 | Amendment | $13,121,905 | $5,599,992vs Nov 21, 2017 | 35 | SEC filing |
| Nov 21, 2017 | Initial | $7,521,913 | No comparison | 13 | SEC filing |
| Dec 28, 2015 | Initial | $6,040,481 | No comparison | 21 | SEC filing |
| Nov 4, 2014 | Initial | $1,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-458709
Total amount sold includes $52,011,674.81 of new cash and $15,631,127.67 of conversion of debt.
Source: Form D, filed Sep 13, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Eric Bednarski | Director |
| Pierre Bertrand | Executive |
| Dean Butler | Director |
| J. Andy Corley | Director, Executive, Promoter |
| J. Andy Corley | Director |
| Davis Corley | Director, Executive |
| Tom Finzi | Director |
| Tom Frinzi | Director |
| Steve Kirby | Director |
| Jeffrey Krall | Promoter |
| William Link | Director |
| Das Narayandas | Director |
| Akhilesh Pathipati | Director |
| Danny Perales | Executive |
| Daniel Perales | Executive |
| Aric Plumley | Executive |
| John Tullis | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1234 Lakeshore Drive #200
Coppell, TX, 75019
Coppell, TX, 75019